The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

Merck MRK announced that the FDA has accepted its supplemental new drug application (sNDA) seeking approval of its oral ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that form in and around the ...

However, the adrenal nodule requires evaluation for possible excess hormone production or suspicion of cancer. A pheochromocytoma is a tumor that produces adrenaline. Adrenaline is commonly associated ...

A former professional basketball player who is battling a rare, incurable form of cancer has urged sufferers “not to let the disease define you” on World Cancer Day. Will Wise, 30, was ...

Paranganglioma tumors arise from bundles of neuroendocrine cells that exist in different locations of the body — from the pelvis, to the spine, to the base of the skull. A pheochromocytoma is a ...

The Department of Urology in AIIMS Bhopal successfully treated 13 hormonally active adrenal tumors in the past year using advanced laparoscopic techniques, demonstrating the institution's innovation ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.